Drug profile · INN
aliskiren hemifumarate
RASILAMLO
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
aliskiren hemifumarate (RASILAMLO) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN aliskiren hemifumarate
Brand RASILAMLO
Route ORAL
Formulation CAPSULE, PELLET
ATC code C09XA53
Frequently asked questions
What is aliskiren hemifumarate?
aliskiren hemifumarate (RASILAMLO) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for aliskiren hemifumarate?
RASILAMLO is a marketed brand name for aliskiren hemifumarate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of aliskiren hemifumarate?
aliskiren hemifumarate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.